Today: 30 June 2026
Applied Materials stock slips after RBC starts coverage at Outperform; what to watch for AMAT next
15 January 2026
2 mins read

Applied Materials stock slips after RBC starts coverage at Outperform; what to watch for AMAT next

NEW YORK, Jan 14, 2026, 18:43 EST — After-hours

  • RBC Capital Markets kicked off coverage of Applied Materials, assigning an Outperform rating and setting a $385 price target
  • BofA raised its price target to $350 and maintained a Buy rating
  • After-hours, AMAT shares slipped roughly 1% to $301.89

RBC Capital Markets kicked off coverage of Applied Materials (AMAT.O) on Wednesday, assigning an Outperform rating and setting a $385 price target. The firm highlighted a stronger outlook for chipmaking-tool demand. After hours, Applied Materials shares dipped roughly 1% to $301.89.

The timing is key as investors shift back into semiconductor capital equipment stocks, betting that spending is expanding beyond the current AI chip bottlenecks. What comes next will hinge less on headlines and more on actual order books — covering memory, logic, and advanced packaging.

China remains a tough wild card. Applied noted that stricter U.S. export rules will limit its reach in the Chinese market, though the company still anticipates a rise in overall tool spending. CFO Brice Hill told investors earlier: “Our customers are indicating to us that wafer fab equipment spending is likely to accelerate beginning in the second half of calendar 2026.” Reuters

On Tuesday, Bank of America boosted its price target for Applied Materials to $350 from $300, maintaining its Buy rating. The firm cited a “stronger multi-year demand outlook,” improved visibility, and the chance for increased free cash flow in the next cycle. TipRanks

RBC analyst Srini Pajjuri noted that while Applied’s shares outperformed the Philadelphia semiconductor index last year, they lagged behind certain U.S. tool peers. He pointed to challenges from China, weaker demand for older “mature” process nodes, and potential shifts in market share as key factors. Pajjuri expects Applied to grow at least in step with wafer fab equipment spending — the gear chipmakers use to operate fabs — with DRAM memory chips driving notable strength.

The note also highlighted longer-term tech shifts: “backside power” (relocating some power connections to a chip’s rear), hybrid bonding in packaging, and novel transistor designs aimed at boosting performance. These changes usually drive more process steps, tools, and service demand as they roll out.

Applied Materials swung between $304.95 and $297.06 on Wednesday, with roughly 6.5 million shares changing hands. Chip-tool peers also slipped: Lam Research (LRCX.O) dropped roughly 3%, while KLA (KLAC.O) dipped about 0.5% late in the session.

There’s a downside risk, though. Should export licensing clamp down again, or if memory and foundry clients pull back after a strong start to the year, price targets won’t hold much weight. These stocks can dive quickly when orders falter.

As regular trading wraps, focus shifts to Thursday’s open, with eyes on whether buyers jump in following the two bullish calls or dismiss them as too little, too late. Traders will also keep an eye on memory spending, where Applied has been pushing hard to prove it holds genuine leverage.

Applied hasn’t set a firm date yet, but earnings are likely due around Feb. 12, according to MarketBeat. Investors will be watching closely for updates on order trends, China exposure, and if management anticipates a smoother spending increase in 2026.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Previous Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Next Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Go toTop